世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

サイコバイオティクス市場の世界産業規模、シェア、動向、競争、機会、予測、2018年~2028年向精神薬別(連鎖球菌、ビフィズス菌、乳酸菌、クロストリジウム、その他)、形態別(粉末、液体/流動体、錠剤、その他)、用途別(ストレス管理、気分の健康・高揚、うつ病、不安、睡眠問題、その他)、地域別、競争状況


Psychobiotics Market Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028Segmented By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others), By Form (Powder, Liquid/Fluid, Tablets, Others), By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others), By Region and Competition

世界のサイコバイオティクス市場は、予測期間2024-2028年に驚異的な成長を遂げると予測されている。市場の成長は、特にストレス、不安、睡眠障害などの精神衛生問題に対する懸念の高まりに起因すると考えられる。... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
TechSci Research
テックサイリサーチ
2023年8月1日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
110 英語

 

サマリー

世界のサイコバイオティクス市場は、予測期間2024-2028年に驚異的な成長を遂げると予測されている。市場の成長は、特にストレス、不安、睡眠障害などの精神衛生問題に対する懸念の高まりに起因すると考えられる。Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019によると、不安障害とうつ病障害は、最も無力な2つの精神疾患であり、2019年の世界的な疾病負担の主要原因の上位25位に入っている。この負担は、男女を問わず、世界中で軒並み重かった。おそらくより重大なことは、その影響を軽減する治療法の強力な証拠があるにもかかわらず、どちらの障害も世界的な有病率や負担が減少していないことである。さらに、COVID-19の突然の流行と、2020年から2021年にかけて世界各国でウイルスを抑制するための封鎖措置がとられたことで、人々の間で精神衛生上の問題が増加している。
サイコバイオティクスとして知られるプロバイオティクスのユニークなカテゴリーが、人々の精神的健康の維持に役立っている。サイコバイオティクスは、神経伝達物質、短鎖脂肪酸、腸内分泌ホルモン、抗炎症性サイトカインの生成を促進する能力があり、一般的なプロバイオティクスとは一線を画している。サイコバイオティクスは、その治療可能性から、ストレスの軽減や気分の改善から、多くの神経発達疾患や神経変性疾患の治療における補助剤まで、幅広い用途がある。乳酸菌、連鎖球菌、ビフィズス菌、エシェリヒア菌、腸球菌のファミリーは、一般的なサイコバイオティクス細菌を含む。市場で入手可能な製品は多くないが、健康志向の人々は入手可能なサイコバイオティクスをうまく利用し、毎日の食習慣に取り入れている。
不安とうつ病を治療するためのプロバイオティクス需要の増加
微生物-腸-脳軸に影響を与えることで、プロバイオティクスは気分と宿主の健康に影響を与えることができる。ストレス、不安、うつ病はすべて、感情が徐々に希薄化することを伴う。不安はストレスに対する反応であるが、それが持続し、治療法を誤ると、うつ病のようなより深刻な精神疾患に発展する可能性がある。ストレスは通常、肉体的または精神的に負担のかかるさまざまな出来事や、緊急の状況に対する短時間の反応から生じる。多くの研究が、人々の不安とうつ病の間に微妙な関係があることを発見している。オーストラリアのデータによると、臨床的に重大な不安を抱える患者の28%がうつ病を併発しており、うつ病患者の約57%が不安も併発していた。
いくつかの研究によると、腸内細菌叢が気分の調節に積極的な役割を果たしていることが証明されており、プロバイオティクスは幅広い用途で利用されている。いくつかの研究によると、大うつ病性障害の被験者では、プロテオバクテリア、バクテロイデーテス、およびアクチノバクテリアの量が増加し、一方ファーミキューテスの量は著しく減少した。プロバイオティクスは中枢神経系の活動や行動にさまざまな影響を及ぼす。まず、一部の局在細菌は、宿主細胞によるセロトニン、ドーパミン、GABAなどの神経伝達物質の産生を誘導することができる。さらに、微生物は脳の神経伝達物質受容体の発現を変化させることができる。抗炎症性サイトカインを増加させ、炎症性サイトカインを減少させることで、プロバイオティクスは全身の炎症抑制にも役立つ。
プロバイオティクスが精神疾患に有効であるという事実を踏まえ、ストレス、不安、うつ病などの精神疾患の治療におけるプロバイオティクスの応用を研究する臨床試験の数も急増している。したがって、このことは今後数年間の世界の精神生物市場の拡大にさらに貢献している。
不安とうつ病の急増
人々に最も頻繁に影響を与える2つの精神疾患は、うつ病と不安障害である。気分障害の主な種類の1つであるうつ病は、気分の落ち込みと興味の喪失が特徴で、罪悪感、絶望感、食欲不振、不眠を伴うことが多い。不安は、緊張感、心配、恐怖のほか、動悸、震え、消化器系、呼吸器系、循環器系の問題など、明確な客観的理由のない身体的変化を伴う。世界保健機関(WHO)の推計によると、2015年には不安障害が3.6%、うつ病が4.4%の世界人口に影響を及ぼすと予測されている。
COVID-19パンデミックは、世界中の患者のメンタルヘルスにも最悪の影響を及ぼした。Lancet』誌に発表された研究によると、不安障害の発症率は全世界で男女ともに25.6%増加した。うつ病の有病率は27.6%増加した。両疾患の有病率の増加は、男性よりも女性で顕著に大きかった。うつ病の有病率は女性で29.8%増加したのに対し、不安障害の有病率は女性で27.9%、男性で21.7%増加した。
消費者意識の高まり
市場の成長は、消費者の消化を含む身体全般のプロセスを改善する精神生物学的能力によっても促進されると予想される。また、胃腸や免疫系など特定の消費者の需要に対応するサイコバイオティクスの能力や、製品開発における最近の進歩の結果、需要も増加すると予測される。
ケリー・グループが2019年に健康志向の米国人2,100人を対象に実施した世界世論調査によると、回答者の62%がプロバイオティクスが何であるかを知っており、32%が過去6カ月間に使用したことがあった。プロバイオティクスを知っているアメリカ人の79%が、消化器系の健康改善が製品に求める最も重要な健康効果であると回答した。
さらに、メーカー各社は、新しい形状、食事条件、パッケージの革新的な精神生物関連製品の開発に力を入れている。メーカーによるビーガンやグルテンフリーのサイコバイオティクス製品の導入により、健康志向でビーガンの消費者の間でサイコバイオティクスの需要が増加している。そのため、改善された健康的なライフスタイルのためにプロバイオティクスを生活に取り入れる人が増えている。このことは、予測される数年間で、サイコバイオティクス産業を増強する可能性が高い。
市場細分化
世界のサイコバイオティクス市場は、向精神薬、形態、用途、地域、企業によって区分される。向精神薬に基づき、市場は連鎖球菌、ビフィズス菌、乳酸菌、クロストリジウム、その他にセグメント化される。形態別では、市場は粉末、液体/流動体、錠剤、その他に分類される。用途別では、ストレス管理、気分の健康&高揚、うつ病、不安、睡眠問題、その他に細分化される。
企業プロフィール
サイコバイオティクスの世界市場で事業を展開している主要企業には、InnovixLabs、Bened Biomedical Co.Ltd.、BioGaia Group、The Life Extension Foundation、Lifted Naturals。

レポートの範囲
本レポートでは、サイコバイオティクスの世界市場を、業界動向に加えて以下のカテゴリーに分類しています:
- サイコバイオティクス市場、向精神薬別
o レンサ球菌
o ビフィズス菌
o 乳酸菌
o クロストリジウム
o その他
- サイコバイオティクス市場、形態別
o 粉末
o 液体/流動体
o 錠剤
その他
- サイコバイオティクス市場:用途別
o ストレス管理
o 気分の健康と気分の高揚
o うつ病
o 不安
o 睡眠問題
o その他
- サイコバイオティクス市場、地域別
o 北米
 米国
 メキシコ
 カナダ
o ヨーロッパ
 フランス
 ドイツ
 イギリス
 イタリア
 スペイン
 スウェーデン
 ポーランド
 スロバキア
o アジア太平洋
 中国
 インド
 韓国
 日本
 オーストラリア
 台湾
 マレーシア
 シンガポール
南米
 ブラジル
 アルゼンチン
 コロンビア
o 中東・アフリカ
 南アフリカ
 サウジアラビア
 UAE
競争環境
企業プロフィール:世界のサイコバイオティクス市場に存在する主要企業の詳細分析。
利用可能なカスタマイズ:
TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供します。本レポートでは以下のカスタマイズが可能です:
企業情報
- 追加市場参入企業(最大5社)の詳細分析とプロファイリング

ページTOPに戻る


目次

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
4.1. Brand Awareness
4.2. Preferred Mode of Purchase
4.3. Major Factors Contributing to Mental Illness
4.4. Willingness towards Psychobiotics Consumption
4.5. Commonly Observed Psychological Effect Post Consumption
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Patents Analysis
7. Global Psychobiotics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
7.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
7.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
7.2.4. By Region
7.2.5. By Company (2022)
7.3. Product Market Map
7.3.1. By Psychotropic Agent
7.3.2. By Form
7.3.3. By Application
7.3.4. By Region
7.4. Pricing Analysis
8. North America Psychobiotics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
8.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
8.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
8.2.4. By Country
8.3. Pricing Analysis
8.4. North America: Country Analysis
8.4.1. United States Psychobiotics Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value & Volume
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Psychotropic Agent
8.4.1.2.2. By Form
8.4.1.2.3. By Application
8.4.1.3. Pricing Analysis
8.4.2. Mexico Psychobiotics Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value & Volume
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Psychotropic Agent
8.4.2.2.2. By Form
8.4.2.2.3. By Application
8.4.2.3. Pricing Analysis
8.4.3. Canada Psychobiotics Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value & Volume
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Psychotropic Agent
8.4.3.2.2. By Form
8.4.3.2.3. By Application
8.4.3.3. Pricing Analysis
9. Europe Psychobiotics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
9.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
9.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
9.2.4. By Country
9.3. Pricing Analysis
9.4. Europe: Country Analysis
9.4.1. France Psychobiotics Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value & Volume
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Psychotropic Agent
9.4.1.2.2. By Form
9.4.1.2.3. By Application
9.4.1.3. Pricing Analysis
9.4.2. Germany Psychobiotics Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value & Volume
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Psychotropic Agent
9.4.2.2.2. By Form
9.4.2.2.3. By Application
9.4.2.3. Pricing Analysis
9.4.3. United Kingdom Psychobiotics Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value & Volume
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Psychotropic Agent
9.4.3.2.2. By Form
9.4.3.2.3. By Application
9.4.3.3. Pricing Analysis
9.4.4. Italy Psychobiotics Market Outlook
9.4.4.1. Market Size & Forecast
9.4.4.1.1. By Value & Volume
9.4.4.2. Market Share & Forecast
9.4.4.2.1. By Psychotropic Agent
9.4.4.2.2. By Form
9.4.4.2.3. By Application
9.4.4.3. Pricing Analysis
9.4.5. Spain Psychobiotics Market Outlook
9.4.5.1. Market Size & Forecast
9.4.5.1.1. By Value & Volume
9.4.5.2. Market Share & Forecast
9.4.5.2.1. By Psychotropic Agent
9.4.5.2.2. By Form
9.4.5.2.3. By Application
9.4.5.3. Pricing Analysis
9.4.6. Sweden Psychobiotics Market Outlook
9.4.6.1. Market Size & Forecast
9.4.6.1.1. By Value & Volume
9.4.6.2. Market Share & Forecast
9.4.6.2.1. By Psychotropic Agent
9.4.6.2.2. By Form
9.4.6.2.3. By Application
9.4.6.3. Pricing Analysis
9.4.7. Poland Psychobiotics Market Outlook
9.4.7.1. Market Size & Forecast
9.4.7.1.1. By Value & Volume
9.4.7.2. Market Share & Forecast
9.4.7.2.1. By Psychotropic Agent
9.4.7.2.2. By Form
9.4.7.2.3. By Application
9.4.7.3. Pricing Analysis
9.4.8. Slovakia Psychobiotics Market Outlook
9.4.8.1. Market Size & Forecast
9.4.8.1.1. By Value & Volume
9.4.8.2. Market Share & Forecast
9.4.8.2.1. By Psychotropic Agent
9.4.8.2.2. By Form
9.4.8.2.3. By Application
9.4.8.3. Pricing Analysis
10. Asia-Pacific Psychobiotics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
10.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
10.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
10.2.4. By Country
10.3. Pricing Analysis
10.4. Asia-Pacific: Country Analysis
10.4.1. China Psychobiotics Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value & Volume
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Psychotropic Agent
10.4.1.2.2. By Form
10.4.1.2.3. By Application
10.4.1.3. Pricing Analysis
10.4.2. India Psychobiotics Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value & Volume
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Psychotropic Agent
10.4.2.2.2. By Form
10.4.2.2.3. By Application
10.4.2.3. Pricing Analysis
10.4.3. South Korea Psychobiotics Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value & Volume
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Psychotropic Agent
10.4.3.2.2. By Form
10.4.3.2.3. By Application
10.4.3.3. Pricing Analysis
10.4.4. Japan Psychobiotics Market Outlook
10.4.4.1. Market Size & Forecast
10.4.4.1.1. By Value & Volume
10.4.4.2. Market Share & Forecast
10.4.4.2.1. By Psychotropic Agent
10.4.4.2.2. By Form
10.4.4.2.3. By Application
10.4.4.3. Pricing Analysis
10.4.5. Australia Psychobiotics Market Outlook
10.4.5.1. Market Size & Forecast
10.4.5.1.1. By Value & Volume
10.4.5.2. Market Share & Forecast
10.4.5.2.1. By Psychotropic Agent
10.4.5.2.2. By Form
10.4.5.2.3. By Application
10.4.5.3. Pricing Analysis
10.4.6. Taiwan Psychobiotics Market Outlook
10.4.6.1. Market Size & Forecast
10.4.6.1.1. By Value & Volume
10.4.6.2. Market Share & Forecast
10.4.6.2.1. By Psychotropic Agent
10.4.6.2.2. By Form
10.4.6.2.3. By Application
10.4.6.3. Pricing Analysis
10.4.7. Malaysia Psychobiotics Market Outlook
10.4.7.1. Market Size & Forecast
10.4.7.1.1. By Value & Volume
10.4.7.2. Market Share & Forecast
10.4.7.2.1. By Psychotropic Agent
10.4.7.2.2. By Form
10.4.7.2.3. By Application
10.4.7.3. Pricing Analysis
10.4.8. Singapore Psychobiotics Market Outlook
10.4.8.1. Market Size & Forecast
10.4.8.1.1. By Value & Volume
10.4.8.2. Market Share & Forecast
10.4.8.2.1. By Psychotropic Agent
10.4.8.2.2. By Form
10.4.8.2.3. By Application
10.4.8.3. Pricing Analysis
11. South America Psychobiotics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value & Volume
11.2. Market Share & Forecast
11.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
11.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
11.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
11.2.4. By Country
11.3. Pricing Analysis
11.4. South America: Country Analysis
11.4.1. Brazil Psychobiotics Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1. By Value & Volume
11.4.1.2. Market Share & Forecast
11.4.1.2.1. By Psychotropic Agent
11.4.1.2.2. By Form
11.4.1.2.3. By Application
11.4.1.3. Pricing Analysis
11.4.2. Argentina Psychobiotics Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1. By Value & Volume
11.4.2.2. Market Share & Forecast
11.4.2.2.1. By Psychotropic Agent
11.4.2.2.2. By Form
11.4.2.2.3. By Application
11.4.2.3. Pricing Analysis
11.4.3. Colombia Psychobiotics Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1. By Value & Volume
11.4.3.2. Market Share & Forecast
11.4.3.2.1. By Psychotropic Agent
11.4.3.2.2. By Form
11.4.3.2.3. By Application
11.4.3.3. Pricing Analysis
12. Middle East and Africa Psychobiotics Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value & Volume
12.2. Market Share & Forecast
12.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
12.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
12.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
12.2.4. By Country
12.3. Pricing Analysis
12.4. MEA: Country Analysis
12.4.1. South Africa Psychobiotics Market Outlook
12.4.1.1. Market Size & Forecast
12.4.1.1.1. By Value & Volume
12.4.1.2. Market Share & Forecast
12.4.1.2.1. By Psychotropic Agent
12.4.1.2.2. By Form
12.4.1.2.3. By Application
12.4.1.3. Pricing Analysis
12.4.2. Saudi Arabia Psychobiotics Market Outlook
12.4.2.1. Market Size & Forecast
12.4.2.1.1. By Value & Volume
12.4.2.2. Market Share & Forecast
12.4.2.2.1. By Psychotropic Agent
12.4.2.2.2. By Form
12.4.2.2.3. By Application
12.4.2.3. Pricing Analysis
12.4.3. UAE Psychobiotics Market Outlook
12.4.3.1. Market Size & Forecast
12.4.3.1.1. By Value & Volume
12.4.3.2. Market Share & Forecast
12.4.3.2.1. By Psychotropic Agent
12.4.3.2.2. By Form
12.4.3.2.3. By Application
12.4.3.3. Pricing Analysis
13. Market Dynamics
13.1. Drivers
13.1.1. Increased Use of Probiotics for Anxiety and Depression
13.1.2. Surge in Subjects with Anxiety and Depression
13.1.3. Tendency of Self-diagnosing and Self-medication amongst the Youth
13.2. Challenges
13.2.1. Detrimental Effects on Physical Health
13.2.2. Endocrine and Metabolic Side Effects
13.2.3. Unavailability in Developing Countries and Under-Developed Countries
14. Market Trends & Developments
14.1. Increasing Number of Clinical Trials
14.2. Increased Competition and Upcoming Innovations
14.3. Mergers & Acquisitions
15. Competitive Landscape
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (As Reported)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. InnovixLabs
15.6.2. Bened Biomedical Co., Ltd
15.6.3. Nutrimmun GmbH
15.6.4. Kerry Group Plc.
15.6.5. Sabinsa Corporation
15.6.6. Lallemand Health Solutions Inc.
15.6.7. DuPont de Nemours, Inc.
15.6.8. Uplift Food Pty Ltd.
15.6.9. Nature's Bounty Co. Ltd.
15.6.10. BioGaia Group
15.6.11. The Life Extension Foundation
15.6.12. Lifted Naturals
16. Strategic Recommendations

 

ページTOPに戻る


 

Summary

Global Psychobiotics market is projected to accomplish extraordinary growth in the forecast period, 2024-2028. The market growth can be attributed to the rising concerns about mental health problems such as stress, anxiety, and sleep disorders, among others. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, anxiety and depression disorders were the two most incapacitating mental diseases, ranking among the top 25 primary causes of disease burden globally in 2019. This burden was heavy across the board, for both sexes, across the globe. Perhaps more crucially, despite strong evidence of therapies that lessen their impact, no decline in either disorder's global prevalence or burden has been observed. Additionally, the sudden outbreak of COVID-19 and the imposition of lockdown to curb the virus in 2020-2021 across different countries around the globe has increased mental health issues among the population.
A unique category of probiotics known as Psychobiotics helps people maintain their mental health. Psychobiotics capacity to create or encourage the formation of neurotransmitters, short-chain fatty acids, enteroendocrine hormones, and anti-inflammatory cytokines sets them apart from typical probiotics. Due to their therapeutic potential, Psychobiotics have a wide range of uses, from reducing stress and improving mood to being an adjuvant in the treatment of many neurodevelopmental and neurodegenerative illnesses. The families of Lactobacilli, Streptococci, Bifidobacteria, Escherichia, and Enterococci include the common psychobiotic bacteria. Although there are not many products available in the market, health-conscious people are making good use of the available psychobiotics and are including them in their daily food routines, thereby amplifying the growth of the global psychobiotic market in the future.
Increasing Demand for Probiotics to Treat Anxiety and Depression
By influencing the microbial-gut-brain axis, probiotics can have an impact on mood and host health. Stress, anxiety, and depression all involve the gradual dilution of emotions. Anxiety is a response to stress, but it can develop into more serious mental diseases like depression if it persists and is mistreated. Stress typically results from a variety of events that are physically or emotionally demanding, as well as from brief responses to urgent circumstances. Numerous studies have discovered a nuanced connection between anxiety and depression in people. According to Australian data, 28% of patients with clinically significant anxiety also had depression, and around 57% of those with depression also had comorbid anxiety.
Based on some research held, it has been proven that the intestinal flora plays an active role in mood regulation and that probiotics find their use in extended applications. Some studies indicate that levels of Proteobacteria, Bacteroidetes, and Actinobacteria were increased in subjects with major depressive disorders, whereas the amounts of Firmicutes decreased significantly. Probiotics have a variety of effects on CNS activity and behavior. First, some localized bacteria can induce the production of neurotransmitters, including serotonin, dopamine, and GABA, by the host's cells. Additionally, microorganisms can change the expression of brain neurotransmitter receptors. By causing an increase in anti-inflammatory cytokines and a decrease in pro-inflammatory cytokines—a pattern connected to the control of intestinal permeability—probiotics also assist in reducing systemic inflammation.
Given the fact that probiotics benefit psychiatric disorders, the number of clinical trials investigating the applications of probiotics in treating mental health disorders such as stress, anxiety, and depression has also proliferated. Hence, this is further aiding in the expansion of the global psychobiotic market in the upcoming years.
Surge in Cases of Anxiety and Depression
The two mental illnesses that affect people the most frequently are depression and anxiety disorders. One of the main types of mood disorders, depression, is characterized by poor mood and loss of interest, frequently accompanied by guilt, hopelessness, loss of appetite, and sleeplessness. Anxiety is a feeling of tension, concern, and fear, as well as bodily changes like palpitations, tremors, and problems with the digestive, respiratory, and circulatory systems that have no clear objective reasons. According to estimates from the World Health Organization (WHO), anxiety disorders were predicted to be 3.6% common, and depression was estimated to affect up to 4.4% of the world's population in 2015.
The COVID-19 pandemic also displayed its worst impacts on the mental health of patients across the world. According to a study published in The Lancet, anxiety disorders increased in incidence among both sexes globally by 25.6%. The prevalence of depressive illness increased by 27.6%. The increase in prevalence for both illnesses was noticeably greater in women than in men. Women had a 29.8% increase in the prevalence of depression, whereas anxiety prevalence was increased by 27.9% in women and by 21.7% in males.
Rising Consumer Awareness
The market’s growth is also anticipated to be fueled by the psychobiotic capacity to improve the body’s general processes, including consumer digestion. Demand is also projected to rise as a result of psychobiotics capacity to address particular consumer demands, such as gastrointestinal and immune systems, and recent advancements in product development.
According to a global poll conducted by Kerry Group in 2019 among 2,100 health-conscious Americans, 62% of respondents knew what probiotics were, and 32% had used them in the previous six months. 79% of Americans who were aware of probiotics responded that improving digestive health was the most important health benefit they look for in a product.
In addition, manufacturers are putting a lot of effort into developing innovative psychobiotic-related products with new forms, dietary requirements, and packaging. Due to the introduction of vegan and gluten-free psychobiotic products by manufacturers, the demand for psychobiotics is increasing among consumers who are health-conscious and vegan. Therefore, more and more people are adopting probiotics in their lives for an improved and healthy lifestyle. This is likely to augment the psychobiotic industry in the forecasted years.
Market Segmentation
Global psychobiotics market is segmented by psychotropic agent, form, application, region, and company. Based on psychotropic agents, the market can be segmented into streptococcus, bifidobacterium, lactobacillus, clostridium, and others. On the basis of form, the market can be categorized as powder, liquid/fluid, tablets, and others. Based on application, the market can be fragmented into stress management, mood health & mood upliftment, depression, anxiety, sleep problems, and others.
Company Profiles
Some of the major players operating in the global psychobiotics market are InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals.

Report Scope:
In this report, global psychobiotics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Psychobiotics Market, By Psychotropic Agent:
o Streptococcus
o Bifidobacterium
o Lactobacillus
o Clostridium
o Others
• Psychobiotics Market, By Form:
o Powder
o Liquid/Fluid
o Tablets
o Others
• Psychobiotics Market, By Application:
o Stress Management
o Mood Health & Mood Upliftment
o Depression
o Anxiety
o Sleep Problems
o Others
• Psychobiotics Market, By Region:
o North America
 United States
 Mexico
 Canada
o Europe
 France
 Germany
 United Kingdom
 Italy
 Spain
 Sweden
 Poland
 Slovakia
o Asia-Pacific
 China
 India
 South Korea
 Japan
 Australia
 Taiwan
 Malaysia
 Singapore
o South America
 Brazil
 Argentina
 Colombia
o Middle East & Africa
 South Africa
 Saudi Arabia
 UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the global psychobiotics market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).



ページTOPに戻る


Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
4.1. Brand Awareness
4.2. Preferred Mode of Purchase
4.3. Major Factors Contributing to Mental Illness
4.4. Willingness towards Psychobiotics Consumption
4.5. Commonly Observed Psychological Effect Post Consumption
5. Clinical Trial Analysis
5.1. Ongoing Clinical Trials
5.2. Completed Clinical Trials
5.3. Terminated Clinical Trials
5.4. Breakdown of Pipeline, By Development Phase
5.5. Breakdown of Pipeline, By Status
5.6. Breakdown of Pipeline, By Study Application
5.7. Breakdown of Pipeline, By Region
5.8. Clinical Trials Heat Map
6. Patents Analysis
7. Global Psychobiotics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
7.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
7.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
7.2.4. By Region
7.2.5. By Company (2022)
7.3. Product Market Map
7.3.1. By Psychotropic Agent
7.3.2. By Form
7.3.3. By Application
7.3.4. By Region
7.4. Pricing Analysis
8. North America Psychobiotics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
8.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
8.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
8.2.4. By Country
8.3. Pricing Analysis
8.4. North America: Country Analysis
8.4.1. United States Psychobiotics Market Outlook
8.4.1.1. Market Size & Forecast
8.4.1.1.1. By Value & Volume
8.4.1.2. Market Share & Forecast
8.4.1.2.1. By Psychotropic Agent
8.4.1.2.2. By Form
8.4.1.2.3. By Application
8.4.1.3. Pricing Analysis
8.4.2. Mexico Psychobiotics Market Outlook
8.4.2.1. Market Size & Forecast
8.4.2.1.1. By Value & Volume
8.4.2.2. Market Share & Forecast
8.4.2.2.1. By Psychotropic Agent
8.4.2.2.2. By Form
8.4.2.2.3. By Application
8.4.2.3. Pricing Analysis
8.4.3. Canada Psychobiotics Market Outlook
8.4.3.1. Market Size & Forecast
8.4.3.1.1. By Value & Volume
8.4.3.2. Market Share & Forecast
8.4.3.2.1. By Psychotropic Agent
8.4.3.2.2. By Form
8.4.3.2.3. By Application
8.4.3.3. Pricing Analysis
9. Europe Psychobiotics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
9.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
9.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
9.2.4. By Country
9.3. Pricing Analysis
9.4. Europe: Country Analysis
9.4.1. France Psychobiotics Market Outlook
9.4.1.1. Market Size & Forecast
9.4.1.1.1. By Value & Volume
9.4.1.2. Market Share & Forecast
9.4.1.2.1. By Psychotropic Agent
9.4.1.2.2. By Form
9.4.1.2.3. By Application
9.4.1.3. Pricing Analysis
9.4.2. Germany Psychobiotics Market Outlook
9.4.2.1. Market Size & Forecast
9.4.2.1.1. By Value & Volume
9.4.2.2. Market Share & Forecast
9.4.2.2.1. By Psychotropic Agent
9.4.2.2.2. By Form
9.4.2.2.3. By Application
9.4.2.3. Pricing Analysis
9.4.3. United Kingdom Psychobiotics Market Outlook
9.4.3.1. Market Size & Forecast
9.4.3.1.1. By Value & Volume
9.4.3.2. Market Share & Forecast
9.4.3.2.1. By Psychotropic Agent
9.4.3.2.2. By Form
9.4.3.2.3. By Application
9.4.3.3. Pricing Analysis
9.4.4. Italy Psychobiotics Market Outlook
9.4.4.1. Market Size & Forecast
9.4.4.1.1. By Value & Volume
9.4.4.2. Market Share & Forecast
9.4.4.2.1. By Psychotropic Agent
9.4.4.2.2. By Form
9.4.4.2.3. By Application
9.4.4.3. Pricing Analysis
9.4.5. Spain Psychobiotics Market Outlook
9.4.5.1. Market Size & Forecast
9.4.5.1.1. By Value & Volume
9.4.5.2. Market Share & Forecast
9.4.5.2.1. By Psychotropic Agent
9.4.5.2.2. By Form
9.4.5.2.3. By Application
9.4.5.3. Pricing Analysis
9.4.6. Sweden Psychobiotics Market Outlook
9.4.6.1. Market Size & Forecast
9.4.6.1.1. By Value & Volume
9.4.6.2. Market Share & Forecast
9.4.6.2.1. By Psychotropic Agent
9.4.6.2.2. By Form
9.4.6.2.3. By Application
9.4.6.3. Pricing Analysis
9.4.7. Poland Psychobiotics Market Outlook
9.4.7.1. Market Size & Forecast
9.4.7.1.1. By Value & Volume
9.4.7.2. Market Share & Forecast
9.4.7.2.1. By Psychotropic Agent
9.4.7.2.2. By Form
9.4.7.2.3. By Application
9.4.7.3. Pricing Analysis
9.4.8. Slovakia Psychobiotics Market Outlook
9.4.8.1. Market Size & Forecast
9.4.8.1.1. By Value & Volume
9.4.8.2. Market Share & Forecast
9.4.8.2.1. By Psychotropic Agent
9.4.8.2.2. By Form
9.4.8.2.3. By Application
9.4.8.3. Pricing Analysis
10. Asia-Pacific Psychobiotics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
10.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
10.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
10.2.4. By Country
10.3. Pricing Analysis
10.4. Asia-Pacific: Country Analysis
10.4.1. China Psychobiotics Market Outlook
10.4.1.1. Market Size & Forecast
10.4.1.1.1. By Value & Volume
10.4.1.2. Market Share & Forecast
10.4.1.2.1. By Psychotropic Agent
10.4.1.2.2. By Form
10.4.1.2.3. By Application
10.4.1.3. Pricing Analysis
10.4.2. India Psychobiotics Market Outlook
10.4.2.1. Market Size & Forecast
10.4.2.1.1. By Value & Volume
10.4.2.2. Market Share & Forecast
10.4.2.2.1. By Psychotropic Agent
10.4.2.2.2. By Form
10.4.2.2.3. By Application
10.4.2.3. Pricing Analysis
10.4.3. South Korea Psychobiotics Market Outlook
10.4.3.1. Market Size & Forecast
10.4.3.1.1. By Value & Volume
10.4.3.2. Market Share & Forecast
10.4.3.2.1. By Psychotropic Agent
10.4.3.2.2. By Form
10.4.3.2.3. By Application
10.4.3.3. Pricing Analysis
10.4.4. Japan Psychobiotics Market Outlook
10.4.4.1. Market Size & Forecast
10.4.4.1.1. By Value & Volume
10.4.4.2. Market Share & Forecast
10.4.4.2.1. By Psychotropic Agent
10.4.4.2.2. By Form
10.4.4.2.3. By Application
10.4.4.3. Pricing Analysis
10.4.5. Australia Psychobiotics Market Outlook
10.4.5.1. Market Size & Forecast
10.4.5.1.1. By Value & Volume
10.4.5.2. Market Share & Forecast
10.4.5.2.1. By Psychotropic Agent
10.4.5.2.2. By Form
10.4.5.2.3. By Application
10.4.5.3. Pricing Analysis
10.4.6. Taiwan Psychobiotics Market Outlook
10.4.6.1. Market Size & Forecast
10.4.6.1.1. By Value & Volume
10.4.6.2. Market Share & Forecast
10.4.6.2.1. By Psychotropic Agent
10.4.6.2.2. By Form
10.4.6.2.3. By Application
10.4.6.3. Pricing Analysis
10.4.7. Malaysia Psychobiotics Market Outlook
10.4.7.1. Market Size & Forecast
10.4.7.1.1. By Value & Volume
10.4.7.2. Market Share & Forecast
10.4.7.2.1. By Psychotropic Agent
10.4.7.2.2. By Form
10.4.7.2.3. By Application
10.4.7.3. Pricing Analysis
10.4.8. Singapore Psychobiotics Market Outlook
10.4.8.1. Market Size & Forecast
10.4.8.1.1. By Value & Volume
10.4.8.2. Market Share & Forecast
10.4.8.2.1. By Psychotropic Agent
10.4.8.2.2. By Form
10.4.8.2.3. By Application
10.4.8.3. Pricing Analysis
11. South America Psychobiotics Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value & Volume
11.2. Market Share & Forecast
11.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
11.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
11.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
11.2.4. By Country
11.3. Pricing Analysis
11.4. South America: Country Analysis
11.4.1. Brazil Psychobiotics Market Outlook
11.4.1.1. Market Size & Forecast
11.4.1.1.1. By Value & Volume
11.4.1.2. Market Share & Forecast
11.4.1.2.1. By Psychotropic Agent
11.4.1.2.2. By Form
11.4.1.2.3. By Application
11.4.1.3. Pricing Analysis
11.4.2. Argentina Psychobiotics Market Outlook
11.4.2.1. Market Size & Forecast
11.4.2.1.1. By Value & Volume
11.4.2.2. Market Share & Forecast
11.4.2.2.1. By Psychotropic Agent
11.4.2.2.2. By Form
11.4.2.2.3. By Application
11.4.2.3. Pricing Analysis
11.4.3. Colombia Psychobiotics Market Outlook
11.4.3.1. Market Size & Forecast
11.4.3.1.1. By Value & Volume
11.4.3.2. Market Share & Forecast
11.4.3.2.1. By Psychotropic Agent
11.4.3.2.2. By Form
11.4.3.2.3. By Application
11.4.3.3. Pricing Analysis
12. Middle East and Africa Psychobiotics Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value & Volume
12.2. Market Share & Forecast
12.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
12.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
12.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
12.2.4. By Country
12.3. Pricing Analysis
12.4. MEA: Country Analysis
12.4.1. South Africa Psychobiotics Market Outlook
12.4.1.1. Market Size & Forecast
12.4.1.1.1. By Value & Volume
12.4.1.2. Market Share & Forecast
12.4.1.2.1. By Psychotropic Agent
12.4.1.2.2. By Form
12.4.1.2.3. By Application
12.4.1.3. Pricing Analysis
12.4.2. Saudi Arabia Psychobiotics Market Outlook
12.4.2.1. Market Size & Forecast
12.4.2.1.1. By Value & Volume
12.4.2.2. Market Share & Forecast
12.4.2.2.1. By Psychotropic Agent
12.4.2.2.2. By Form
12.4.2.2.3. By Application
12.4.2.3. Pricing Analysis
12.4.3. UAE Psychobiotics Market Outlook
12.4.3.1. Market Size & Forecast
12.4.3.1.1. By Value & Volume
12.4.3.2. Market Share & Forecast
12.4.3.2.1. By Psychotropic Agent
12.4.3.2.2. By Form
12.4.3.2.3. By Application
12.4.3.3. Pricing Analysis
13. Market Dynamics
13.1. Drivers
13.1.1. Increased Use of Probiotics for Anxiety and Depression
13.1.2. Surge in Subjects with Anxiety and Depression
13.1.3. Tendency of Self-diagnosing and Self-medication amongst the Youth
13.2. Challenges
13.2.1. Detrimental Effects on Physical Health
13.2.2. Endocrine and Metabolic Side Effects
13.2.3. Unavailability in Developing Countries and Under-Developed Countries
14. Market Trends & Developments
14.1. Increasing Number of Clinical Trials
14.2. Increased Competition and Upcoming Innovations
14.3. Mergers & Acquisitions
15. Competitive Landscape
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (As Reported)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. InnovixLabs
15.6.2. Bened Biomedical Co., Ltd
15.6.3. Nutrimmun GmbH
15.6.4. Kerry Group Plc.
15.6.5. Sabinsa Corporation
15.6.6. Lallemand Health Solutions Inc.
15.6.7. DuPont de Nemours, Inc.
15.6.8. Uplift Food Pty Ltd.
15.6.9. Nature's Bounty Co. Ltd.
15.6.10. BioGaia Group
15.6.11. The Life Extension Foundation
15.6.12. Lifted Naturals
16. Strategic Recommendations

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

TechSci Research社の世界/地域別市場調査分野での最新刊レポート

本レポートと同じKEY WORD(industry)の最新刊レポート


よくあるご質問


TechSci Research社はどのような調査会社ですか?


テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22 10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る